

**Supplemental Table 1. Comparison of general information and intraoperative conditions between control group and LIPOC group**

	Control group	LIPOC group	P-value
<b>Gender (male/female)</b>	7/1	7/1	
<b>Age (years)</b>	49.6±4.8	51.2±3.8	0.6626
<b>Weight (kg)</b>	59.7±6.1	58.3±5.6	0.2147
<b>ASA grade (I / II)</b>	2/6	3/5	
<b>History of hepatitis B (Yes/No)</b>	6/2	5/3	
<b>Tumor size (cm)</b>	4.8±2.3	5.1±2.6	0.5539
<b>Occlusion time (min)</b>	19.2±2.8	18.7±2.1	0.9677
<b>Operative time (min)</b>	176.3±23.4	182.5±26.2	0.5836
<b>Blood loss volume (mL)</b>	398.4±162.8	374.9±180.2	0.7368
<b>Blood transfusion volume (mL)</b>	226.4±114	225.9±122.0	0.3506
<b>Fluid infusion volume (mL)</b>	1876.0±312.4	1865.9±331.6	0.7546
<b>Intraoperative urine volume (mL)</b>	232.4±138.7	221.8±160.3	0.7576
<b>Liver cirrhosis (Yes/No)</b>	3/5	4/4	

**Supplemental Table 2: The effects of LIPOC and its combination with LY294002 and PD98059 on the regulation of the levels of Akt and ERK1/2 mRNAs in liver tissues**

Group	Akt mRNA	ERK1 mRNA	ERK2 mRNA
<b>S</b>	1.00±0.24	1.00±0.43	1.00±0.31
<b>LY+S</b>	0.92±0.55	1.01±0.43	1.39±0.74
<b>PD+S</b>	0.94±0.48	1.08±0.47	0.93±0.22
<b>I/R</b>	1.15±0.60	1.32±0.26	1.10±0.58
<b>LIPOC</b>	1.03±0.41	1.11±0.68	1.10±0.93
<b>LY+LIPOC</b>	1.09±0.42	1.40±0.69	0.96±0.35
<b>PD+LIPOC</b>	0.85±0.29	1.01±0.56	1.06±0.27

The measurement data were  $2^{-\Delta\Delta Ct}$  value expressed as mean ± standard deviation, n=6.